GSK

Business Context and Reporting Period

This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2, 2016. The report serves as a regulatory update regarding the development timeline for a closed triple combination therapy (fluticasone furoate/umeclidinium/vilanterol) for patients with chronic obstructive pulmonary disease (COPD), in collaboration with Innoviva, Inc.

Key Financial Metrics

The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory announcement focused on clinical development and filing plans rather than financial performance.

Material Changes

• Accelerated US Filing: GSK has accelerated the planned filing of a New Drug Application (NDA) in the US for the closed triple combination therapy. The submission is now expected by the end of 2016, a significant shift from the previously anticipated first half of 2018.
• EU Filing Timeline: The company continues to expect an EU regulatory submission for the therapy by the end of 2016.

Guidance, Outlook, and Risks

Outlook and Management Commentary: The accelerated US filing is based on discussions with the FDA and utilizes data currently in hand from the development program, alongside data from studies involving the individual components (FF, UMEC, VI). The therapy is not yet approved for use anywhere in the world. Clinical Program Status:

• FULFIL Study: Expected to read out later in 2016 to support EU filing. It assesses lung function and quality of life compared to Symbicort.
• IMPACT Study: Expected to read out in 2017. It investigates the reduction of exacerbation rates compared to existing dual therapies.

Risks and Contingencies: Both GSK and Innoviva include standard cautionary statements regarding forward-looking statements. Risks include the potential for actual results to differ materially from projections due to regulatory delays, clinical study outcomes, and commercialization uncertainties. Innoviva specifically notes risks related to royalty revenue dependence and third-party collaboration.

Investor Verification Checklist

• Verify the final submission date of the US NDA for FF/UMEC/VI against the end-of-2016 target.
• Monitor the readout dates for the FULFIL and IMPACT clinical studies to ensure they align with the 2016 and 2017 expectations.
• Review FDA and EMA regulatory decisions following the anticipated 2016 submissions.
• Assess the commercial impact of the triple therapy on GSK's existing respiratory portfolio (e.g., ANORO, BREO).